NICE backs Tafinlar

The U.K.'s NICE issued a Tafinlar dabrafenib from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to treat adults with unresectable or metastatic melanoma with a BRAF V600 mutation, its approved indication.

Tafinlar, which is recommended at 150 mg twice daily and comes in 28-capsule packages, has a list price of L1,400 ($2,275) for a 75 mg capsule package and L933.33 ($1,517) for a 50 mg capsule package. The pharma has agreed to provide the oral BRAF protein kinase inhibitor at an undisclosed discount under a patient access scheme, upon which NICE's recommendation is contingent. ...